Table 1. Patient Characteristics DP Arm MVP Arm PS of 0/1 46/53 50/51 Median age (range) 65 (40–75) 64 (34–75) Weight loss (<5% / >5%) 88/11 89/12 Stage IIIA/IIIB 33/66 33/68

Table 2. Overall Survival DP Arm MVP Arm OS Event Rate 95% CI 95%CI 1 year 17 82.8% 73.8–88.9 32 68.2% 58.2–76.4 2 year 39 60.3% 49.9–69.2 52 48.5% 38.4–57.8 3 year 62 36.4% 26.9–45.9 61 39.4% 29.8–48.8 4 year 73 24.7% 16.5–33.6 78 22.2% 14.7–30.8

EURTAC Preliminary Interim Analysis Results CT Arm (n=76) Erlotinib (n=77) P-value Response rate 10.5% 54.5% <0.0001 PFS [95% CI] 5.2 months [4.4–5.8] 9.4 months [7.9–12.3] [HR 0.42] Median survival 18.8 months 22.9 months 0.42 [HR 0.80] Common toxicities (% patients) Asthenia (68.9%) Anemia (45.9%) Nausea (40.5%) Neutropenia (36.5%) Diarrhea (57.3%) Asthenia (53.35) Rash (49.3%) –

Grade 3–4 Toxicities Toxicity Thalidomide No Treatment P-value Low platelet count 6 11 0.31 Leukopenia 2 3 – Constipation Neurosensory problems Cardiovascular events* NOTES *Cardiovascular events were not considered treatment related